CytoDyn Inc. appointed Michael Klump to its board as a director.

Klump, who is also a significant CytoDyn investor, is the founder, president and CEO of private equity firm Argonne Capital Group LLC.

Vancouver, Wash.-based CytoDyn develops humanized monoclonal antibodies to treat and prevent HIV infection. Its lead drug candidate is PRO 140, a humanized immunoglobulin G4, or igG4, monoclonal antibody that blocks the cellular receptor implicated in HIV infection, tumor metastasis and immune signaling.